| Net sales | 5,439.5a | 5,010a | 4,464a |
| Cost of sales | -1,117.5a | -978.4a | -723.7a |
| Gross profit | 4,322a | 4,031.6a | 3,740.3a |
| Selling, general, and administrative expenses | -1,789.2a | -1,582.5a | -1,357.6a |
| Research and development expenses | -1,053a | -962.9a | -843.6a |
| Intellectual property agreement and certain litigation expenses | -40.4a | -203.5a | -15.8a |
| Change in fair value of contingent consideration liabilities | | -26.2a | -35.8a |
| Restructuring charges, separation costs, and other | -61a | | -60.7a |
| Other operating income, net | -0.3a | | |
| Operating income | 1,378.7a | 1,308.9a | 1,498.4a |
| Interest expense | -19.8a | -17.6a | -19.2a |
| Interest income | -120.3a | -67.2a | -35.5a |
| Other non-operating income, net | -68.9a | -13.9a | -4.8a |
| Income from continuing operations before provision for income taxes | 1,548.1a | 1,372.4a | 1,519.5a |
| Provision for income taxes | -152.1a | -152.4a | -195.5a |
| Net income from continuing operations | 1,396a | 1,220a | 1,324a |
| Income from discontinued operations, net of tax | 2,773.7a | 179.4a | 197.9a |
| Net income | 4,169.7a | 1,399.4a | 1,521.9a |
| Net loss attributable to noncontrolling interest | -4.9a | -3a | |
| Net income attributable to Edwards Lifesciences Corporation | 4,174.6a | 1,402.4a | 1,521.9a |